Julian Symons
Chief Tech/Sci/R&D Officer at ALIGOS THERAPEUTICS, INC.
Net worth: 322 344 $ as of 30/04/2024
Julian Symons active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 | - |
Career history of Julian Symons
Former positions of Julian Symons
| Companies | Position | Start | End |
|---|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/2013 | 01/04/2018 |
Training of Julian Symons
| University of Central Lancashire | Undergraduate Degree |
| York University | Doctorate Degree |
Statistics
International
| United States | 3 |
| United Kingdom | 2 |
| Canada | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Julian Symons
- Experience